Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Health Care · CIK 0001521036
$100.10
-0.14% · delayed ~15 min
Last price from Oct 22, 2026
$6.47B market value
From Lantheus Holdings, Inc.'s FY2025 10-K, filed Feb 26, 2026 · read the filing
Lantheus develops and makes medicines. It took in $1.54B last year, which makes it a mid-sized company. Of every dollar it sells, about 15 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 4 insiders, not under a pre-arranged plan.
$1.3M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From Lantheus Holdings, Inc.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating margin
29.8% → 20.2%
Cash
$912.8M → $359.1M
Operating income
$457.0M → $310.8M
Profit
$312.4M → $233.6M
Measured against FY2024, from the 10-K filed Feb 26, 2026
Deteriorated: −9.6 pts
29.8% to 20.2%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
How the latest move compares (quote delayed ~15 min), and what was published around it
LNTH fell 0.14% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 1.8 points below its sector and 0.9 points above the market.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 5% a year for the next 10 years. Over the last 10 years it grew by about 45% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 15 cents of every dollar of sales as profit, earning $233.6M last year.
Barely. Sales were roughly flat, up 0.5%.
No. Its borrowings would take under a year of cash flow to clear. For every $1 it owes, it owns $1.96 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $233.6M and generated $390.1M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 26, 2026Filing for FY2025 | FY202410-K · Feb 26, 2026Filing for FY2024 | FY202310-K · Feb 22, 2024Filing for FY2023 | FY202210-K · Feb 22, 2024Filing for FY2022 | FY202110-K · Feb 23, 2023Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $1.54B | $1.53B | $1.30B | $935.1M | $425.2M | +0.5% |
| Cost of revenue | $599.7M | $545.6M | $586.9M | $353.4M | $237.5M | +9.9% |
| Gross profit | $942.0M | $988.3M | $709.5M | $581.7M | $187.7M | −4.7% |
| Gross marginGross profit ÷ revenueWhat is this? | 61.1% | 64.4% | 54.7% | 62.2% | 44.1% | −3.3 pts |
| Selling, general and administrative | $275.1M | $193.7M | $125.5M | $133.6M | $150.4M | +42.0% |
| Operating income | $310.8M | $457.0M | $364.6M | $36.2M | -$60.8M | −32.0% |
| Operating marginOperating income ÷ revenueWhat is this? | 20.2% | 29.8% | 28.1% | 3.9% | -14.3% | −9.6 pts |
| Interest expense | $19.7M | $19.7M | $20.0M | $7.2M | $7.8M | +0.4% |
| Income before tax | $313.8M | $431.0M | $410.9M | $26.7M | -$75.0M | −27.2% |
| Net income | $233.6M | $312.4M | $326.7M | $28.1M | -$71.3M | −25.2% |
| Net marginNet income ÷ revenueWhat is this? | 15.2% | 20.4% | 25.2% | 3.0% | -16.8% | −5.2 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $3.62 | $4.56 | $4.68 | $0.4076 | $-1.05 | −20.8% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| LNTHLantheus Holdings, Inc. · this page | 9.0/10 | 5/9 | 0.5% | 15.2% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 80,783 shares at $3.11 ($250.9K)
Holds 11,440,513 shares after this filing.
Sold on the open market — 167,149 shares at $3.15 ($526.1K)
Holds 11,273,364 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Reported another event
Read the filingHeld a shareholder vote
Read the filingWrite down why you are following Lantheus Holdings, Inc., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 32 subsidiaries named in its 10-K, incorporated across 9 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from LNTH's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 26, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 5/9 | 10-K, filed Feb 26, 2026 |
| FY2024 | 10.0 | 6/9 | 10-K, filed Feb 26, 2025 |
| FY2023 | 10.0 | 7/9 | 10-K, filed Feb 22, 2024 |
| FY2022 | 6.0 | 8/9 | 10-K, filed Feb 23, 2023 |
| FY2021 | 6.0 | 7/9 | 10-K, filed Feb 24, 2022 |
| FY2020 | 2.0 | 3/9 | 10-K, filed Feb 25, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
5 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
5.29
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.28
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: -60.7%
$912.8M to $359.1MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: -32.0%
$457.0M to $310.8MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -25.2%
$312.4M to $233.6MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −3.3 pts
64.4% to 61.1%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: −5.2 pts
20.4% to 15.2%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -28.2%
$493.1M to $354.1MSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -20.8%
$4.56 to $3.62Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -5.6%
68.5M to 64.6MSignificant
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Changed: -30.1%
$51.6M to $36.1MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 6, 2026 — read it.
Improved: -9.0%
71.7M to 65.3MSignificant
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Improved: +13.9%
$88.0M to $100.2MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: −1.5 pts
63.8% to 62.3%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +2.5 pts
23.3% to 25.8%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −1.5 pts
20.8% to 19.3%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -14.7%
$695.6M to $593.3MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 6, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: −12.0 pts
31.4% to 19.3%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +23.2%
$81.3M to $100.2MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -36.6%
$118.4M to $75.0MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +4.3 pts
21.6% to 25.8%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: -36.8%
$1.82 to $1.15Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +19.0%
$498.6M to $593.3MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +1.1 pts
61.2% to 62.3%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 3% and 7%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 16 analysts covering this company, as of . Their views, not this site's.
Of 16 analysts publishing on this company, 2 say strong buy, 6 say buy and 8 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 5.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 21.6x — investors pay $21.6 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 27.68x |
| 1.04x |
| ALGNALIGN TECHNOLOGY INC | 8.7/10 | 6/8 | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
| Median of peers | 8.7/10 | — | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 42,129 shares at $3.11 ($131.2K)
Holds 11,521,296 shares after this filing.
Sold on the open market — 35,769 shares at $3.12 ($111.6K)
Holds 11,563,425 shares after this filing.
Had shares withheld to cover taxes — 721 shares at $100.96 ($72.8K)
Holds 122,071 shares after this filing.
Sold on the open market — 78,145 shares at $3.14 ($245.6K)
Holds 11,599,194 shares after this filing.
Had shares withheld to cover taxes — 463 shares at $100.91 ($46.7K)
Holds 13,263 shares after this filing.
Had shares withheld to cover taxes — 2,536 shares at $100.91 ($255.9K)
Holds 33,195 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Reported another event
Reported another event
Read the filingQuarterly report for Q2 FY2026
Operating margin +2.5 pts · Shares in issue -9.0% · Operating income +13.9% — against Q2 FY2025
Read the filingPublished results
Read the filingSigned a material agreement · Had a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingQuarterly report for Q1 FY2026
Operating margin −5.8 pts · Profit +62.3% · Profit margin +11.8 pts — against Q1 FY2025
Read the filingPublished results
Read the filingChanged the rights attached to its shares · Had a director or senior officer leave or join · Amended its charter or changed its financial year · Held a shareholder vote
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Operating margin −9.6 pts · Cash -60.7% · Operating income -32.0% — against FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q3 FY2025
Operating margin −24.0 pts · Operating income -67.4% · Profit -78.8% — against Q3 FY2024
Read the filingHad a director or senior officer leave or join · Published results · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q2 FY2025
Operating margin −2.8 pts · Profit +26.9% · Profit margin +5.1 pts — against Q2 FY2024
Read the filingPublished results · Made a Regulation FD disclosure · Reported another event
Read the filingSource: Exhibit 21 of the 10-K filed 2026-02-26. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Yahoo Finance ·
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Yahoo Finance ·
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
Yahoo Finance ·
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
Yahoo Finance ·
3 Reasons LNTH is Risky and 1 Stock to Buy Instead
Yahoo Finance ·
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Yahoo Finance ·
2 Small-Cap Stocks to Consider Right Now and 1 That Underwhelm
Yahoo Finance ·
Curium acquisition of Lantheus backed by $5.375B of debt financing
Yahoo Finance ·
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
Yahoo Finance ·
Lantheus Reports Second Quarter 2026 Financial Results
Yahoo Finance ·
1 Healthcare Stock Worth Your Attention and 2 We Question
Yahoo Finance ·
1 Russell 2000 Stock with Exciting Potential and 2 That Underwhelm
Yahoo Finance ·
Primary sources and further research